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ABSTRACTSBackground: Both orthopaedic surgery and cast immobilisation are
independent risk factors for development of VTE1. There are currently no
guidelines on appropriate risk stratiﬁcation or treatment for this cohort of
patients2. The potentially signiﬁcant ﬁnancial cost of prophylaxis has
previously not been established.
Aims: To perform an economic analysis to determine the potential costs
and beneﬁts of the above treatment.
Methods: Data from one hundred patients who had undergone lower limb
immobilisation were prospectively collected using a specially designed
proforma. Information included personal demographics, diagnosis and
adjusted risk factors for VTE.
A decision tree model from a NHS perspective was used to calculate both
cost of prophylaxis and cost of VTE diagnosis, treatment and long term
complications. Incremental cost-effectiveness ratios (ICER) were calcu-
lated to provide estimates of the cost per VTE averted, and cost per quality-
adjusted life year (QALY) gained with the use of thromboprophylaxis.
Discussion 46/100 patients with primary lower limb cast immobilisation
qualiﬁed for prophylaxis. This numberof patientswould incur a prophylaxis
cost of £9113.52, however would save an estimated £3617.44 in direct VTE
diagnosis and treatment costs and £19,847.10 in long-term costs. This
resulted in a cost per VTE averted of £3338.10 and cost perQALYof £9623.58.
There are substantial cost implications in using thromboprophylaxis for
cast immobilised patients, however it has been demonstrated that this
may be cost effective in the long term. Using a more selective risk strati-
ﬁcation tool may reduce direct prophylaxis costs and increase short term
cost effectiveness.
SYMPTOMS SUGGESTIVE OF DUMPING SYNDROME AFTER PROVOCATION
IN PATIENTS AFTER LAPAROSCOPIC SLEEVE GASTRECTOMY
Dimitris Papamargaritis a, George Tzovaras a, Eleni Sioka a, Eleni Zachari a,
Ioannis Baloyiannis a, Dimitris Zacharoulis a, George Koukoulis b.
aDepartment of Surgery, University Hospital of Larissa, Greece; bDepartment
of Endocrinology, University Hospital of Larissa, Greece
Background: Dumping syndrome is a well-known complication after
upper gastrointestinal (GI) surgery. There are scarce data in the literature
about the incidence of dumping after bariatric operations but, certainly no
relation between this syndrome and laparoscopic sleeve gastrectomy
(LSG) has been attempted.
Methods: We conducted a prospective clinical study in order to evaluate
the potential presence, incidence and severity of Dumping syndrome after
LSG. Thirty one non-diabetic morbidly obese patients (eight male, 23
female) eligible for LSG were evaluated. Median age was 38 (22e58 years)
and mean body mass index (BMI) was 45.55 (5.37). The diagnosis of
dumping syndrome was based on clinical provocation of signs and
symptoms using an oral glucose challenge before and 6 weeks after the
operation. The Sigstad's dumping score was estimated in order to separate
dumpers from non-dumpers, and the Arts questionnaire was completed to
distinguish between early and late dumping. Moreover, blood glucose
levels during the oral glucose challenge were measured.
Results: No patient had symptoms of dumping after provocation preop-
eratively, whereas after LSG 9 patients (29%) experienced deﬁnite
dumping and other 5 patients (16%) symptoms suggestive of dumping
syndrome. Arts’ questionnaire demonstrated that dumping occurrence
after LSG was associated with early symptoms. Late hypoglycaemia
occurred in one patient.
Conclusion: A signiﬁcant proportion of patients after LSG experienced
dumping syndrome upon provocation. It seems that LSG should no longer
be considered as a pure restrictive procedure, and it might be an option for
heavy sweeters by changing their food tolerance patterns.
APPEARANCES CAN BE DECEIVING e GENETIC HETEROGENEITY IN THE
COLON OF CANCER PATIENTS
E. Day a,b, F. McCaughan a, A. Ibrahim c, M. Arends c, P.H. Deara a. aMRC
Laboratory of Molecular Biology, Cambridge, United Kingdom; bUniversity of
Cambridge School of Clinical Medicine, United Kingdom; cDepartment of
Pathology, University of Cambridge, United Kingdom
Background: Distinct histological features physically deﬁne a colorectal
carcinoma (CRC) and distinguish it from the normal colon mucosa. Often,however, there are regions adjacent to a carcinoma that deviate from the
normal histological appearance and display features of hyperplasia and/or
adenoma. It is not certain whether these regions represent precursor
lesions or reactive changes. To address this we have characterised a series
copy number alterations (CNAs) that typify CRC in the regions adjacent to
a carcinoma.
Methods: Micro-dissection molecular copy number counting (mMCC) was
used to assay CNAs frequently observed in CRC and those known to
contribute to carcinogenesis. mMCC employs laser capture micro-dissec-
tion to accurately collect DNA from speciﬁc histological regions and uses
single molecule digital PCR to measure copy number. Four CRC cases were
characterised.
Results: In the normal colon we describe genetic heterogeneity and
identify CNAs that are known to contribute to tumour formation, namely
KRAS ampliﬁcation. In addition a number of copy number changes are
shared by and built on in the hyperplastic, adenomatous and carcinoma
samples.
Conclusion: These preliminary data support the model of step-wise
cancer progression but importantly suggest that nearby hyperplastic
regions may represent precursors rather than reactive changes. These
results have implications on our understanding of CRC pathogenesis and
practically on the optimal location of resection boundaries in CRC surgery.
Further work is now needed to establish how widespread CNAs are in the
normal colon and regions adjacent to CRC.
THE QUALITY OF REPORTING IN RANDOMISED CONTROLLED TRIALS IN
PLASTIC SURGERY
Eric Edison. UCL Medical School, United Kingdom
Introduction: Randomised controlled trials (RCTs) represent the gold
standard in evaluating healthcare interventions. However, RCTs can yield
biased results if they lack methodological rigour, especially where surgical
techniques are involved. Readers need complete, clear and transparent
information. The Consolidated Standards of Reporting Trials (CONSORT)
statement for non-pharmacological interventions was developed to aid
reporting and consists of a 23 essential items.
Aim: To assess the compliance of RCTs in Plastic Surgery with the
CONSORT statement.
Method: Medline was searched by an information specialist from 1
January 2009 to 30 June 2011 for the MESH heading “Surgery, Plastic” with
limitations for English language, human studies and randomised
controlled trials. Results were then manually searched for relevant RCTs
involving surgical techniques. These were scored against the 23 item
CONSORT checklist. Secondary scoring was then performed and discrep-
ancies resolved by consensus.
Results: 55 papers involving 3,830 patients met the inclusion criteria from
a manual search of 254 papers retrieved from Medline. The average
CONSORT score was 11.5 out of 23 items (50%, range 5.3e21.0). Compliance
was poorest with items related to intervention/comparator details (7%),
randomisation implementation (11%) and blinding (26%). There was no
link between journal 2010 impact factor and CONSORT score (R ¼ 0.25).
Only 60% declared conﬂicts of interest and 75% had permission from an
ethics committee.
Conclusion: The reporting quality of RCTs in Plastic Surgery is poor.
Importantly, those aspects central to RCT methodology (randomisation
and blinding) were the most poorly reported.
FUNCTIONAL HEALTH STATUS OF PATIENTS AFTER THE FONTAN
OPERATION
Hanieh Asadi General Medicine Diploma work a,b,1. aDepartment of
Pediatric Cardiothoracic Surgery, Comenius University in Bratislava Medical
Faculty, Slovakia; b The National Institute of Cardiovascular Diseases, Comenius
University in Bratislava Medical Faculty, Slovakia
Background: The Fontan procedure is a palliative procedure for the single
ventricle, existing for about four decades. A retrospective study was made
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ABSTRACTSto determine the functional health status of patients who had undergone
the procedure.
Methods: The study included 189 patients undergoing the procedure
between 1983 and 2010, 78 females and 111males (mean age 8.39 years). A
child health questionnaire CHQ-PF50 was ﬁlled in by the parents. The
scores were transformed into a 0-100 scale and divided into physical and
psychosocial functioning. Data was collected by reviewing hospital records
and analysis carried out with the JMP statistical software.
Results: The group of respondents was 25 out of 100, out of which 15
identiﬁed patients. 14 patients from the whole cohort were deceased. The
highest score of the physical (PhS) functioning: 76.27, the psychosocial
(PsS) functioning: 62.44. The lowest score for the PhSwas 16.03 and for PsS
11.43. Mean score for PhS was 40.05 and for PsS 47.34. The median years
after the Fontan operation: 3.6 years and the median age: 4.4 years. The
results show the mean PhS being below the average for the general U.S
population while just below the average in PsS.
Conclusions: The functional health outcome of patients after the Fontan
operation is below the average in a physical aspect and just below the
average psychosocially.
Considering it is a complex congenital heart disease this might bewhat can
be expected from these individuals.
Keywords: Cardiac surgery, Single ventricle, Fontan procedure, Functional
health outcome
ENDOSCOPIC PALLIATION OF MALIGNANT BILIARY OBSTRUCTION. ARE
METAL STENTS WORTH THE COST?
Hayley Heffernan, Irina Baimatova, Gemma Gossedge, Mike Zeiderman.
Southport District General Hospital, United Kingdom
Introduction: This study was designed to determine whether the use of
plastic stents should be abandoned on the basis of effectiveness and cost.
Method: The records of all patients with malignant biliary obstruction,
who underwent ERBD at Southport Hospital between 2005 and 2010, were
reviewed. Patients with nonmalignant biliary obstruction, obstruction due
to other primary malignancies and those lost to follow up were excluded.
The incidence of complications, patency rates, readmissions and time
spent in hospital were recorded. Cost was calculated from NHS tariff of
ERCP + plastic stent at £835 and metal stent at £1496.
Results: 49 patients were included. M:F 27:22. Median age 77 years (range
59e96). 46 patients had plastic stents and 3 had metal stents inserted.
Diagnoses e pancreatic carcinoma (36), cholangiocarcinoma (8), ampul-
lary carcinoma (5). Median bilirubin at time of ﬁrst ERCP e 301 mmol/L
(range 62e759).
There were no immediate procedure-related complications.
Eight patients (17%) represented with blocked plastic stents at a median
time of 80 days (range 3e280). Of these, 6 patients had a plastic and one
had a metal stent re-inserted.
If primary treatment had been with metal stents then the cost would have
been £73,304. Allowing for readmissions and stent changes, total cost for
the plastic stent group was £47,301, a saving of £26,003.
Conclusion: Plastic stents provide long-term palliation of ERBD for the
majority of patients and should be accepted as ﬁrst line treatment. The cost
of primary treatment with metal stents cannot be justiﬁed.
QUALITY OF LIFE AFTER THERAPEUTIC MAMMOPLASTY
Dr. Iram Haq, K.L. Kirkpatrick, G. Mitchell, A.P. Tansley. Mersey Foundation
School (FY1), United Kingdom
Aims: Therapeutic mammaplasty (TM) is increasingly used to treat breast
tumours where breast size allows; no data exists for subsequent Quality of
Life (QoL). This pilot study assessed QoL to provide evidence for TM as an
appropriate technique.
Methods: A QoL questionnaire was employed incorporating six validated
tools including the European Organisation for Research and Treatment of
Cancer QoL questionnaire for breast cancer, on patients undergoing TM
from 2006 to 2010. Cosmesis was judged by medical and non-medical
personnel.
Results: 46 patients (average BMI 30 kg/m2 (range 23e40)), underwent
TM, 96% for malignancy. Preoperative estimated breast volume was
226d2592 cm3 (mean 1061cm3), predicted percentage resection 0.8e35%(mean 10%); ultimate average resection was 258 g (36e1067 g). Compli-
cations predominantly fat necrosis, occurred in 24%, ﬁve patients required
completion mastectomy, 96% received adjuvant radiotherapy.
QoL scores (n¼36) were excellent with a mean of 73% [95% CI 68e78],
psychosexual function subset scored highest (83%). Mean cosmesis score
was 67% [95% CI 61e73], comparable with previously reported data. QoL
increased by 14% from 6 months to 3 years despite 10% cosmesis decline.
Conclusion: This study suggests good sustained QoL after TM, supporting
its use in selected patients. Mastectomy may not be avoided and coun-
seling should reﬂect this.
LONG TERM OUTCOMES OF CYCLODIODE THERAPY FOR RAISED
INTRAOCULAR PRESSURE AT A UK TEACHING HOSPITAL
Ivailo Zhekov. University of Cambridge Clinical School, United Kingdom
Aim: The main aims of this study were to investigate the dose-response
relation of the cyclodiode treatment and to evaluate possible predictive
factors that would help establish optimum parameters. The outcomes of
the procedure were evaluated both post-operatively and through long-
term follow-up.
Methods: A retrospective review of 87 patients who underwent trans-
scleral diode laser cyclophotocoagulation procedure from 2004 through
2011.
Results: Mean intraocular pressure (IOP) decreased signiﬁcantly from
39.54 mmHg (SE 1.26) before cyclodiode therapy to 17.83 mmHg (SE 1.51)
post-treatment, a reduction of 45.09% (p< 0.0001). This wasmeasured at 6
weeks andmaintained for 3 years. Pressure reduction of>30% of initial IOP
was achieved in 72.34% of the patients. This was greater (80.3%) in the
group receiving extensive treatment (90J). In addition, a signiﬁcant
proportion of the patients that underwent cyclodiode therapy (63.45%)
decreased their number of IOP lowering medications postoperatively from
2.56 to 1.59. Hypotony occurred in 5.31% of patients, predominantly in
patients receiving extensive treatment (90e120J), however none of the
patients developed further complications or required enucleation. Neo-
vascular glaucoma was a signiﬁcant risk factor. Visual acuity (VA)
remained unchanged or improved for the majority of the patients under-
going a cyclodiode procedure (83.55%) and was maintained long-term.
Conclusion: Cyclodiode therapy is a highly effective method for achieving
reduction of Intraocular Pressure and long-term maintenance of Visual
Acuity in patients with glaucoma.
A MULTICENTRE NATIONAL AUDIT OF THE RECORDING OF PATIENTS
WEIGHT: IMPLICATIONS FOR THE PRESCRIPTION OF GENTAMICIN
AND THERAPEUTIC-DOSE LOW MOLECULAR WEIGHT HEPARIN
Dr. Jamie Willson, Dr. Sebastian Thomas, Mr. Jonathan Horsnell, Dr.
Soumen Sen, Dr. Strachan Mackenzie, Dr. Arti Patel, Dr. William Ratliff,
Dr. Sabrina Black, Dr. Sarasvati Chauhan, Dr. Alice Armitage, G.P. Tarr, Dr.
Kathryn Garnham, Dr. Alistair Robb. Imperial College School of Medicine
(FY2), United Kingdom
Objectives: Identify the percentage of patients being weighed in hospital
and the proportion of these prescribed gentamicin or therapeutic dose low
molecular weight heparin (t-LMWH).
Design: Retrospective review of drug charts and bedside notes of all
secondary care hospital inpatients across 5 wards; 2medical, 2 surgery and
1 peadiatrics chosen at random in 11 hospitals in England and Wales.
Results: A total of 48.5% (515/1061) of hospital inpatients had their weight
recorded (paediatric wards 98% (77/78), adult wards 45.8% (438/983)). The
range of recording between hospitals was 23.0% and 93.3%. In total 113
patients audited were receiving either Gentamicin of t-LMWH; 65.2% (73/
113) of which had a recorded weight. Of those receiving t-LMWH: 74.2%
(49/66) were weighed vs 56.6% (30/53) of those receiving Gentamicin.
There was large variation between hospitals in recording weight of
patients receiving Gentamicin or t-LMWH, 25.0%e100% (1/4e6/6).
Conclusions: Over half of the inpatients are not being weighed in hospital,
falling short of NICE and DoH guideline to weigh all hospital patients. This
failure leaves patients at risk of undetected malnutrition, which increases
the risk of mortality, post-operative complications and lengthened
hospitals stays. Furthermore, patient on drugs requiring a weight speciﬁc
dose, are at greater risk of severe side effects or subtherapeutic drug
